Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 223-228

  Dookie, Navisha ^a   Sturm, A Willem ^a   Moodley, Prashini ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Drug resistance; Fluoroquinolones; Strain typing; Susceptibility testing

Indexed keywords

BACTERIAL DNA; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA EXTRACTION; GENE MUTATION; GENOTYPE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTH AFRICA;

EID: 84906775499     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S65417     Document Type: Article

References (25)

1. World Health Organization. Global Tuberculosis Report 2013. Geneva: WHO; 2013. Available from: http://www.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1. Accessed July 9, 2014.
2. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3(7):432-442.
3. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51(1):6-14.
4. Poissy J, Aubry A, Fernandez C, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother. 2010;54(11): 4765-4771.
5. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis. 2001;32 Suppl 1:S16-S22.
6. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;67(5):1088-1093.
7. Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relation to antimicrobial exposure. J Antimicrob Chemother. 2007;59(5):860-865.
8. Von Groll A, Martin A, Jureen P, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother. 2009;53(10):4498-4500.
9. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New Insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012;7(6):e39754.
10. Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother. 2013;57(9):4496-4500.
11. World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis. 4th ed. Geneva: WHO; 2009. Available from: http://www.who.int/entity/tb/publications/2009/surveillance_guidelines/en/index.html. Accessed February 21, 2013.
12. Angeby KA, Jureen P, Giske CG, et al. Wild-type distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother. 2010;65(5):946-952.
13. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 1991;29(11):2578-2586.
14. Rozen S, Skaletsky HJ. Primer3: Pick primers from a DNA sequence. 2009. Available from: http://frodo.wi.mit.edu/primer3. Accessed January 14, 2014.
15. Geneious [website on the Internet]. Available from: http://www.geneious.com. Accessed January 14, 2014.
16. Van Embden JD, Cave MD, Crawford JT, et al. Strain Identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31(2):406-409.
17. Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66(7):1417-1430.
18. Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012;67(4):819-831.
19. Feasey NA, Pond M, Coleman D, et al. Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2010;15(3):417-420.
20. South Africa Department of Health. Management of Drug-Resistant Tuberculosis: Policy Guidelines. Pretoria: Department of Health; 2011.
21. Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012;12(3):176-177; author reply 177-178.
22. Ramtahal MA. Spread of Multidrug Resistant Tuberculosis (MDR) Including Extensively Drug Resistant Tuberculosis (XDR), in Rural KwaZulu-Natal, South Africa [master's thesis]. Durban: University of KwaZulu-Natal; 2012.
23. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9574): 1575-1580.
24. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 9th ed. Wayne (PA): CLSI; 2012. Available from: http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/03-CLSI-M07-A9-2012.pdf. Accessed May 14, 2014.
25. Gandhi NR, Brust JCM, Moodley P, et al. Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerg Infect Dis. 2014;20(3):426-433.